Language
繁體中文
簡體中文
English
關於保盛About Us
Company Profile
Management Team
Milestones
Plant & Quality
Join Us
Contact
Products
研究與發展Research & Development
High Barrier Generics
投資人關係
Shareholder Services
Corporate Governance
Unaudited Monthly Sales
Financial Report
Shareholder Contacts
新聞發佈News & Media
News
Announcement
News
Announcement
Home > News & Media > News
Communication starts here.
2021-01
TWi officially launches generic Dimethyl Fumarate DR Capsules in TWi label
2020-10
TWi’ ANDA for Dimethyl Fumarate DR Capsules (equivalent to Tecfidera®) has been officially approved by US FDA
2020.08
TWi officially launches generic Propafenone HCl ER Capsules in TWi label
2020.07
TWi officially launches generic Terbutaline Sulfate Tablets in TWi label
2020.07
TWi successfully launches generic Fenofibric Acid DR Capsules in TWi label
2020.06
TWi's ANDA for Terbutaline Sulfate Tablets (equivalent to Brethine®) has been officially approved by US FDA
2020.06
TWi's ANDA for Propafenone HCl ER Capsules (equivalent to Rythmol SR®) has been officially approved by US FDA
2020.03
TWi successfully launches generic Testosterone Gel 1.62% Pump CIII in TWi label
2019.11
TWi successfully launches generic Sevelamer Carbonate Tablets in TWi label
2019.11
TWi successfully launches generic Metoprolol Succinate ER Tablets in TWi label
Pages:
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
« Pre
·
Next »